Trial Profile
Dose Ranging, Single Dose Safety and Pharmacokinetic Study of DUR-928 in Subjects with Nonalcoholic Steatohepatitis (NASH) and Control Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Apr 2017
Price :
$35
*
At a glance
- Drugs Larsucosterol (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Pharmacokinetics
- 24 Apr 2017 According to a DURECT Corporation media release, data from this study were presented at The International Liver CongressTM 2017 (the 52nd annual meeting of the European Association for the Study of the Liver (EASL)).
- 24 Apr 2017 Results published in a DURECT Corporation media release.
- 30 Jan 2017 Results published in the DURECT Corporation Media Release